Endoscopic mucosal resection

Motus GI Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023
News, Workforce, Gastrointestinal disease, University, Atmosphere, Minneapolis, EMR, Minneapolis Veterans Affairs Health Care System, Endoscopic mucosal resection, Banner Desert Medical Center, EVS, Carbon, Ministry, Hospital, Pentax, MD, Patient, Physician, IBP, Gastroenterology, Ecuadorian Institute of Social Security, R, FDA, MVA, Medical device, Pharmaceutical industry, Cassette tape, Health

The Company incurred non-recurring charges related to these cost-cutting measures of approximately $1.5 million in the first half of 2023.

Key Points: 
  • The Company incurred non-recurring charges related to these cost-cutting measures of approximately $1.5 million in the first half of 2023.
  • Financial Results for the Second Quarter Ended June 30, 2023
    The Company reported revenue of $113,000 for the second quarter 2023, compared to $185,000 for the same period last year.
  • The Company reported $8.5 million in cash and cash equivalents as of June 30, 2023.
  • The Company believes that its cash and cash equivalents as of June 30, 2023 will be sufficient to allow the Company to fund its commercial, R&D and corporate operations through the first quarter of 2024.

Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 at the Pentax Learning Center

Retrieved on: 
Wednesday, June 14, 2023
Suction, Atmosphere, Gastrointestinal disease, EMR, Motus, Endoscopic mucosal resection, Carbon, Pentax, MD, Patient, Physician, Blood, Ecuadorian Institute of Social Security, Mortality, Research, GI, Pharmaceutical industry

The Pure-Vu Gen 4 system will have a new mode called “fluid only” that the user can select when needed to support this new use case of UEMR.

Key Points: 
  • The Pure-Vu Gen 4 system will have a new mode called “fluid only” that the user can select when needed to support this new use case of UEMR.
  • “We are pleased by the positive feedback our Pure-Vu Gen 4 system received from physicians participating in the IECED course 2023,” commented Mark Pomeranz, Chief Executive Officer.
  • “We believe the advanced capabilities of this important next generation of our technology is continuing to generate broad interest in the Pure-Vu system.
  • The Company is also leveraging this Gen 4 technology to enhance the Pure-Vu device in the colon.

Motus GI Completes First Clinical Evaluation of New Pure-Vu® Gastro in Upper Gastrointestinal (GI) Procedures to Support FDA Submission

Retrieved on: 
Wednesday, May 17, 2023
Hematochezia, Suction, EURO, Gastrointestinal disease, WEO, ISO, Anatomy, Endoscopic mucosal resection, Endoscopy, Colon, Certification, Pentax, MD, Patient, Physician, EUS, Blood, Ecuadorian Institute of Social Security, Diagnosis, Mortality, Research, GI, Medical device, Medical imaging

FORT LAUDERDALE, Fla., May 17, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced in collaboration with the Ecuadorian Institute of Digestive Diseases (IECED) initiation of a clinical evaluation of the Pure-Vu Gen 4 Gastro, which is designed for upper gastrointestinal (GI) bleeding procedures - an area of high unmet patient need.

Key Points: 
  • “We are excited to initiate this important clinical evaluation of the Pure-Vu Gen 4 Gastro with Dr. Carlos Robles-Medranda and the team at IECED.
  • The focus of these procedures was aimed at evaluating the device’s ability to improve a physician’s visualization while identifying and treating upper GI bleeds.
  • Dr. Robles-Medranda has already successfully conducted his first series of procedures utilizing the Pure-Vu Gen 4 Gastro and provided positive initial feedback on the device’s performance.
  • The procedures in the upper GI tract were efficient for these first time users with the upper procedures averaging only 11 minutes.

Agilis RoboticsTM Completes New Round of Live Animal Trials with Miniaturized Robotic Instruments for Endoscopic Surgery

Retrieved on: 
Tuesday, January 17, 2023
Animal, Medtronic, R, Infection, University, Learning curve, Agilis, Endoscopic mucosal resection, COVID-19, ESD, GI, Cancer, CFO, Intuitive Surgical, Colorectal cancer, Endoscopy, Laparoscopy, Safety, Surgeon, Risk, Human body, Robotics, Dissection, Johnson & Johnson, Neurosurgery, University of Hong Kong-Shenzhen Hospital, AI, Internal medicine, Conditional sentence, Artificial intelligence, Patient, EMR, Growth, Urology, Colonoscopy, NOTES, NMPA, General surgery, Gastrointestinal disease, Deep learning, Optimism, Multimedia, Gastrointestinal tract, Dietary supplement, Dentistry, Medical imaging, Medical device, 3D printing

HONG KONG, Jan. 16, 2023 /PRNewswire/ -- Agilis RoboticsTM (Agilis), a leading developer of flexible robotic instruments that support endoscopic surgery through natural orifices of the body (e.g.

Key Points: 
  • HONG KONG, Jan. 16, 2023 /PRNewswire/ -- Agilis RoboticsTM (Agilis), a leading developer of flexible robotic instruments that support endoscopic surgery through natural orifices of the body (e.g.
  • along the gastrointestinal tract and in the bladder), has recently completed the second round of live animal testing using its proprietary robot.
  • The Agilis RoboticsTM system is a surgical robotic solution designed for endoscopic surgery.
  • Second, the newly developed endoscope holder offers the surgeon great flexibility for positioning the endoscope and robotic instruments.

Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab

Retrieved on: 
Monday, December 19, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, DCR, Roberto Lamarca, EAP, BeiGene, Webcast, Epitope, DOR, COVID-19, BTC, Systematic review, Safety, Conjugation, Corr, Research, Engineering, Patient, CLIN, HER2, Inc., IHC, Authorization, Endoscopic mucosal resection, Cohort, Progression-free survival, Tislelizumab, Drug development, Response evaluation criteria in solid tumors, Diagnosis, GEA, Gallbladder cancer, Cholangiocarcinoma, ISH, ICR, Adjuvant, Security (finance), RECIST, Drug Quality and Security Act, Clinical trial, Jazz, In situ hybridization, PFS, Zymeworks, Legislation, Pharmaceutical industry, Medical imaging

The safety profile of zanidatamab in this trial was consistent with that observed in previously reported monotherapy studies, with no new safety signals identified.

Key Points: 
  • The safety profile of zanidatamab in this trial was consistent with that observed in previously reported monotherapy studies, with no new safety signals identified.
  • Full results from the pivotal trial are expected to be presented at a medical meeting in 2023.
  • Zymeworks is developing zanidatamab in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2.
  • Zymeworks continues to enroll subjects in the Phase 3 randomized clinical trial, HERIZON-GEA-01, evaluating zanidatamab in combination with chemotherapy plus or minus tislelizumab for HER2-expressing GEA.

Olympus Announces EMEA Expansion of Exclusive Partnership with EndoClot Plus, Inc.

Retrieved on: 
Thursday, December 8, 2022
Polyp, Physician, Medicine, Endoscopic mucosal resection, Partnership, Patient, Hemostasis, Adenoma, Laparoscopy, ESD, Endoscopy, Olympus, Quality of life, News, Multimedia, Safety, EPI, EMR, Pharmaceutical industry, Medical device, GI

WESTBOROUGH, Mass., Dec. 8, 2022 /PRNewswire/ -- Olympus, a global medical technology company focused on designing and delivering innovative solutions for medical and surgical procedures, announced today a new exclusive distribution agreement with EndoClot® Plus, Inc. (EPI) that extends our strategic partnership to the Europe, Middle East and Africa (EMEA) region. This news follows a successful commercialization of the EndoClot product portfolio in the United States, announced in April 2022.

Key Points: 
  • This news follows a successful commercialization of the EndoClot product portfolio in the United States, announced in April 2022.
  • EPI technologies complement Olympus' comprehensive portfolios in GI (gastrointestinal) endoscopy and the company's overall medtech strategy.
  • "We are very excited to expand our global partnership with Olympus," said Stephen Heniges, President, EPI.
  • "With Olympus' support in the U.S. and now EMEA, we expect that more healthcare providers and their patients will be able to benefit from our solutions.

FUJIFILM Europe launches new software for SCALE EYE¹, a real-time virtual scale function to aid endoscopists in estimating the size of lesions in the colon

Retrieved on: 
Thursday, October 6, 2022
Physician, Colon, Endoscopy, Diagnosis, Vaccine, CAD, Patient, Gastrointestinal Endoscopy, Polyp (medicine), Research, Colonoscopy, Support, Colorectal cancer, Technology, Cancer, Deep learning, ESGE, Software, World Cancer Day, Percussion section, Endoscopic mucosal resection, AI, Incidence, Health, EYE, ESD, Photography, Artificial intelligence, GLOBE, SCALE, EMR, Regenerative medicine, Large intestine, Solution, European Commission, Medical imaging, Telescopic sight, Medical device, Fujifilm

RATINGEN, Germany, Oct. 06, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Europe GmbH has launched the new software EW10-VM01 for SCALE EYE real-time virtual scale function (“SCALE EYE”), designed to help endoscopists estimate the size of lesions in the colon. SCALE EYE is the latest technology to be launched as part of the ELUXEO Ultra platform, delivering a comprehensive package for endoscopists.

Key Points: 
  • RATINGEN, Germany, Oct. 06, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Europe GmbH has launched the new software EW10-VM01 for SCALE EYE real-time virtual scale function (SCALE EYE), designed to help endoscopists estimate the size of lesions in the colon.
  • Fujifilm has developed SCALE EYE, a function designed to aid endoscopists in estimating the size of lesions in the colon.
  • The SCALE EYE system includes the newly developed endoscope EC-760S-A/M, L, which is equipped with a class 1 laser.
  • 1 SCALE EYE is a Fujifilm brand name of function to support size estimation by virtual scale.

EsoCap holds a multidisciplinary advisory board meeting on Barrett’s esophagus

Retrieved on: 
Tuesday, June 14, 2022
GERD, Adult, EOE, Mometasone, BE, Hepatology, Safety, Survival, Gastroesophageal reflux disease, Risk factor, EMR, Esophageal, Pathology, Radiofrequency ablation, University of Greifswald, Orphan, Smoking, Mouth, Stomach, API, Center, Transport, University, FDA, GLOBE, Patient, Division, RFA, Risk, Technology, Phase, Barrett's esophagus, Survival rate, Endoscopic mucosal resection, Obesity, EAC, Population, Department, Board, Consultant, Cancer, Mayo Clinic, Esophagus, Extrapyramidal system, Eosinophilic esophagitis, Internal medicine, Health insurance, Pharmaceutical industry, Dentistry, Dietary supplement, Gastroenterology

The EsoCap technology is a potential game changer in the treatment of Barretts esophagus.

Key Points: 
  • The EsoCap technology is a potential game changer in the treatment of Barretts esophagus.
  • The participants in this scientific advisory board meeting included eight distinguished experts from Europe, Switzerland and the USA, all internationally recognized for their expertise in Barretts esophagus.
  • I am highly impressed by the wealth of expertise shared in this meeting, said Dr Werner Tschollar, Chairman of the Board of EsoCap.
  • We are committed to working closely with the experts to advance our development programme in Barretts esophagus with the EsoCap unique topical drug delivery technology.

3-D Matrix Medical Technology’s PuraStat® Hemostatic Gel Highlighted by Key Opinion Leaders at Digestive Disease Week®

Retrieved on: 
Thursday, May 26, 2022
Newton, Hemostasis, American Society for Gastrointestinal Endoscopy, Physician, American Gastroenterological Association, ERCP, Medicine, American Association for the Study of Liver Diseases, ESD, Incidence, Endoscopy, 2021 Essex County Council election, Patient, AGA, Radiation, Institute of Liver and Biliary Sciences, MIT, Society, Association, Research, Gastroenterology, Queen Alexandra Hospital, Bleeding, Matrix, Technology, ASGE, AASLD, Gastrointestinal tract, Extrapyramidal system, Gastrointestinal disease, Endoscopic mucosal resection, American Association, SSAT, EMR, DDW, Gastrointestinal Endoscopy, Perforation, GLOBE, Pharmaceutical industry, Birth control, GI

Newton, MA, May 26, 2022 (GLOBE NEWSWIRE) -- PuraStat, a hemostatic agent made by 3-D Matrix Medical Technology, a leading global peptide solutions company, was prominently featured in several key presentations from key opinion leaders at the recent Digestive Disease Week (DDW).

Key Points: 
  • Newton, MA, May 26, 2022 (GLOBE NEWSWIRE) -- PuraStat, a hemostatic agent made by 3-D Matrix Medical Technology, a leading global peptide solutions company, was prominently featured in several key presentations from key opinion leaders at the recent Digestive Disease Week (DDW).
  • He concluded his presentation by saying, In our hands, we have seen significant reduction in delayed bleeding rates.
  • Professor Repici provided real-time visual evidence of how PuraStat enables precise application for prevention of post-procedural bleeding.
  • PuraStats hemostatic gel features a unique, self-assembling synthetic peptide designed to reduce delayed bleeding and achieve hemostasis during endoscopic procedures in the gastrointestinal tract.

Coding for Minimally Invasive Endoscopic Treatments Are Now Available

Retrieved on: 
Monday, April 18, 2022
Per-oral endoscopic myotomy, Center, Endoscopy, Esophageal achalasia, Awareness, Government, CPT, Mayo Clinic, Center for Medicare and Medicaid Innovation, EMR, Colonoscopy, Group, FARS, Patient, GI, Endoscopic mucosal resection, ESD, Olympus Corporation, Laparoscopy, Clinical professor, HCPCS, Neoplasm, Safety, Physician, Partnership, HCP, Quality of life, Centers for Medicare & Medicaid Services, American Medical Association, Medicare, Health insurance, Medical device, Medical imaging

CENTER VALLEY, Pa., April 18, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, today announced its support of a new reimbursement from the Centers for Medicare and Medicaid Services that is expected to improve patient access to Endoscopic Submucosal Dissection (ESD) and for per-oral endoscopic myotomy (POEM). Both are minimally invasive procedures performed endoluminally as an alternative to open or laparoscopic surgery.

Key Points: 
  • Both are minimally invasive procedures performed endoluminally as an alternative to open or laparoscopic surgery.
  • Effective Jan. 1, 2022, a new level 1 CPT code is available for 43497, lower esophageal myotomy transoral, i.e.
  • Compared to Endoscopic Mucosal Resection (EMR), ESD allows for the complete en bloc removal rather than piecemeal resection of large tumors greater than 2 cm.
  • "These decisions also present potential to raise patient and HCP awareness about treatment options that are available.